Common cholesterol drug may shield myeloma patients from chemo nerve pain

NCT ID NCT07025005

Recruiting now Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether fenofibrate, a drug typically used for high cholesterol, can prevent or reduce nerve damage caused by a common chemotherapy regimen for multiple myeloma. The trial will enroll 44 newly diagnosed patients, half receiving fenofibrate alongside their standard treatment and half receiving standard treatment alone. Researchers will measure nerve damage through questionnaires and blood tests over six treatment cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fenofibrate
What this could lead to: If it works, fenofibrate could become a simple, low-cost way to prevent painful nerve damage in multiple myeloma patients undergoing chemotherapy.
What could go wrong: This is a small, early-phase study with only 44 participants. The results may not apply to all patients, and fenofibrate may not reduce nerve damage as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA, NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm peripheral nervous system disorder peripheral neuropathy plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA, NEOPLASMS PERIPHERAL NEUROPATHY

Contacts and locations

Locations

Damanhur Oncology Center
RECRUITING

Damanhur, El- Behira, Egypt
Tanta University
RECRUITING

Tanta, El-Gharbya, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.